findmyKOL

Carlton Fenzl, MD

Basic profile

Scott Community College

ORCIDNone on fileNPI
RegionBettendorf, IA · MidwestSpecialtyOphthalmologyFocusOphthalmology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Carlton Fenzl is an Ophthalmology physician affiliated with Scott Community College. OpenAlex indexes 22 publications with 497 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
22publications

Distinct works indexed by OpenAlex.

497citations

Total citations across indexed works.

10h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    78.1%
    Antineovascularisation agents55.3%
    Faricimab-svoa100%
    Part B, office-administered14 patients
    Corticosteroid10.4%
    Prednisolone Acetate93%Fluorometholone7%
    Part D583 patients

    + 8 more classes in this area

  • Cancer & immunology

    9.7%
    Vascular Endothelial Growth Factor Inhibitor8.1%
    Aflibercept78%Bevacizumab22%
    Part B, office-administered45 patients
    Calcineurin inhibitor1.5%
    Restasis80%Cyclosporine20%
    Part D47 patients
  • Anti-infectives

    8.5%
    Fluoroquinolone Antibacterial7.8%
    Moxifloxacin100%
    Part D574 patients
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.4%
    Valacyclovir100%
    Part D11 patients

    + 1 more class in this area

Where care is delivered (Part B)7.6% facility · 92.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”